Differences between group X and group V secretory phospholipase A(2) in lipolytic modification of lipoproteins. 2012

Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
Department of Molecular Bacteriology, RIMD, Osaka University, 3-1, Yamada-oka, Suita-shi, Osaka, 565-0871, Japan. skami@biken.osaka-u.ac.jp

Secretory phospholipases A(2) (sPLA(2)s) are a diverse family of low molecular mass enzymes (13-18 kDa) that hydrolyze the sn-2 fatty acid ester bond of glycerophospholipids to produce free fatty acids and lysophospholipids. We have previously shown that group X sPLA(2) (sPLA(2)-X) had a strong hydrolyzing activity toward phosphatidylcholine in low-density lipoprotein (LDL) linked to the formation of lipid droplets in the cytoplasm of macrophages. Here, we show that group V sPLA(2) (sPLA(2)-V) can also cause the lipolysis of LDL, but its action differs remarkably from that of sPLA(2)-X in several respects. Although sPLA(2)-V released almost the same amount of fatty acids from LDL, it released more linoleic acid and less arachidonic acid than sPLA(2)-X. In addition, the requirement of Ca(2+) for the lipolysis of LDL was about 10-fold higher for sPLA(2)-V than sPLA(2)-X. In fact, the release of fatty acids from human serum was hardly detectable upon incubation with sPLA(2)-V in the presence of sodium citrate, which contrasted with the potent response to sPLA(2)-X. Moreover, sPLA(2)-X, but not sPLA(2)-V, was found to specifically interact with LDL among the serum proteins, as assessed by gel-filtration chromatography as well as sandwich enzyme-immunosorbent assay using anti-sPLA(2)-X and anti-apoB antibodies. Surface plasmon resonance studies have revealed that sPLA2-X can bind to LDL with high-affinity (K(d) = 3.1 nM) in the presence of Ca(2+). Selective interaction of sPLA(2)-X with LDL might be involved in the efficient hydrolysis of cell surface or intracellular phospholipids during foam cell formation.

UI MeSH Term Description Entries
D008066 Lipolysis The metabolic process of breaking down LIPIDS to release FREE FATTY ACIDS, the major oxidative fuel for the body. Lipolysis may involve dietary lipids in the DIGESTIVE TRACT, circulating lipids in the BLOOD, and stored lipids in the ADIPOSE TISSUE or the LIVER. A number of enzymes are involved in such lipid hydrolysis, such as LIPASE and LIPOPROTEIN LIPASE from various tissues. Lipolyses
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002951 Citrates Derivatives of CITRIC ACID.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.

Related Publications

Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
August 2008, Journal of internal medicine,
Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
December 2001, FEBS letters,
Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
June 2002, European journal of clinical investigation,
Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
October 2003, Biochimica et biophysica acta,
Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
January 2006, The Biochemical journal,
Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
July 2000, FEBS letters,
Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
November 2014, Journal of thrombosis and haemostasis : JTH,
Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
March 2022, Lipids,
Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
November 1999, Trends in cardiovascular medicine,
Shigeki Kamitani, and Katsutoshi Yamada, and Shigenori Yamamoto, and Yoshikazu Ishimoto, and Takashi Ono, and Akihiko Saiga, and Kohji Hanasaki
August 2002, Cancer letters,
Copied contents to your clipboard!